{
    "nctId": "NCT05747313",
    "briefTitle": "Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer",
    "officialTitle": "A Prospective, Single-arm, Open-lable, Single-center Phase Ib/II Clinical Study of Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Chemotherapy Effect",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female;\n* aged \u2265 18 years and \u226475 years;\n* histologically proved metastatic triple-negative breast cancer;\n* at least one measurable or evaluable lesion based on RECIST 1.1 criteria;\n* estimated life expectancy \u2265 3 months; (6) normal heart, liver, and kidney function;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; -\n* informed consent signed by the participants.\n\nExclusion Criteria:\n\n* received neoadjuvant or adjuvant therapy containing vinorelbine or capecitabine within one year prior to treatment initiation;\n* participated in other new drug clinical trials within 4 weeks before enrollment;\n* inflammatory breast cancer;\n* symptomatic visceral disease;\n* second primary malignancy;\n* mental disorder.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}